-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Aclaris Therapeutics Analyst Ratings
Aclaris Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/07/2023 | 176.77% | Cantor Fitzgerald | → $38 | Reiterates | → Overweight |
| 12/14/2022 | 111.22% | Stifel | → $29 | Initiates Coverage On | → Buy |
| 12/01/2022 | 82.08% | Goldman Sachs | → $25 | Initiates Coverage On | → Buy |
| 10/06/2022 | 133.07% | BTIG | → $32 | Initiates Coverage On | → Buy |
| 06/16/2021 | 264.17% | HC Wainwright & Co. | $40 → $50 | Maintains | Buy |
| 06/15/2021 | 118.5% | Piper Sandler | → $30 | Initiates Coverage On | → Overweight |
| 04/21/2021 | 191.33% | HC Wainwright & Co. | → $40 | Initiates Coverage On | → Buy |
| 03/04/2021 | 89.37% | SVB Leerink | $21 → $26 | Maintains | Outperform |
| 01/20/2021 | 52.95% | SVB Leerink | $4.5 → $21 | Maintains | Outperform |
| 10/23/2019 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
| 10/22/2019 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
| 09/06/2019 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 08/09/2019 | -63.58% | Cantor Fitzgerald | $24 → $5 | Reiterates | → Overweight |
| 06/27/2019 | — | SVB Leerink | Downgrades | Outperform → Market Perform | |
| 05/06/2019 | — | SVB Leerink | Initiates Coverage On | → Outperform | |
| 10/16/2018 | 147.63% | JMP Securities | $47 → $34 | Maintains | Market Outperform |
| 03/28/2018 | 278.73% | Leerink Swann | $54 → $52 | Maintains | Outperform |
| 03/13/2018 | 293.3% | Leerink Swann | $56 → $54 | Maintains | Outperform |
| 02/09/2018 | 286.02% | Guggenheim | → $53 | Initiates Coverage On | → Buy |
What is the target price for Aclaris Therapeutics (ACRS)?
The latest price target for Aclaris Therapeutics (NASDAQ: ACRS) was reported by Cantor Fitzgerald on February 7, 2023. The analyst firm set a price target for $38.00 expecting ACRS to rise to within 12 months (a possible 176.77% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aclaris Therapeutics (ACRS)?
The latest analyst rating for Aclaris Therapeutics (NASDAQ: ACRS) was provided by Cantor Fitzgerald, and Aclaris Therapeutics reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Aclaris Therapeutics (ACRS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aclaris Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aclaris Therapeutics was filed on February 7, 2023 so you should expect the next rating to be made available sometime around February 7, 2024.
Is the Analyst Rating Aclaris Therapeutics (ACRS) correct?
While ratings are subjective and will change, the latest Aclaris Therapeutics (ACRS) rating was a reiterated with a price target of $0.00 to $38.00. The current price Aclaris Therapeutics (ACRS) is trading at is $13.73, which is within the analyst's predicted range.
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/07/2023 | 176.77% | Cantor Fitzgerald | → $38 | Reiterates | → Overweight |
| 12/14/2022 | 111.22% | Stifel | → $29 | Initiates Coverage On | → Buy |
| 12/01/2022 | 82.08% | Goldman Sachs | → $25 | Initiates Coverage On | → Buy |
| 10/06/2022 | 133.07% | BTIG | → $32 | Initiates Coverage On | → Buy |
| 06/16/2021 | 264.17% | HC Wainwright & Co. | $40 → $50 | Maintains | Buy |
| 06/15/2021 | 118.5% | Piper Sandler | → $30 | Initiates Coverage On | → Overweight |
| 04/21/2021 | 191.33% | HC Wainwright & Co. | → $40 | Initiates Coverage On | → Buy |
| 03/04/2021 | 89.37% | SVB Leerink | $21 → $26 | Maintains | Outperform |
| 01/20/2021 | 52.95% | SVB Leerink | $4.5 → $21 | Maintains | Outperform |
| 10/23/2019 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
| 10/22/2019 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
| 09/06/2019 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 08/09/2019 | -63.58% | Cantor Fitzgerald | $24 → $5 | Reiterates | → Overweight |
| 06/27/2019 | — | SVB Leerink | Downgrades | Outperform → Market Perform | |
| 05/06/2019 | — | SVB Leerink | Initiates Coverage On | → Outperform | |
| 10/16/2018 | 147.63% | JMP Securities | $47 → $34 | Maintains | Market Outperform |
| 03/28/2018 | 278.73% | Leerink Swann | $54 → $52 | Maintains | Outperform |
| 03/13/2018 | 293.3% | Leerink Swann | $56 → $54 | Maintains | Outperform |
| 02/09/2018 | 286.02% | Guggenheim | → $53 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 02/07/2023 | 176.77% | 康托·菲茨杰拉德 | →$38 | 重申 | →超重 |
| 2022年12月14日 | 111.22% | Stifel | →$29 | 开始承保 | →购买 |
| 12/01/2022 | 82.08% | 高盛 | →$25 | 开始承保 | →购买 |
| 10/06/2022 | 133.07% | BTIG | →$32 | 开始承保 | →购买 |
| 06/16/2021 | 264.17% | HC Wainwright公司 | $40→$50 | 维护 | 买 |
| 2021/06/15 | 118.5% | 派珀·桑德勒 | →$30 | 开始承保 | →超重 |
| 04/21/2021 | 191.33% | HC Wainwright公司 | →$40 | 开始承保 | →购买 |
| 03/04/2021 | 89.37% | SVB Leerink | $21→$26 | 维护 | 跑赢大盘 |
| 01/20/2021 | 52.95% | SVB Leerink | $4.5→$21 | 维护 | 跑赢大盘 |
| 2019年10月23日 | - | SVB Leerink | 升级 | 市场表现优于→ | |
| 2019年10月22日 | - | SVB Leerink | 升级 | 市场表现优于→ | |
| 2019年06月09日 | - | JMP证券 | 评级下调 | 市场表现优于→市场表现 | |
| 2019年08月09日 | -63.58% | 康托·菲茨杰拉德 | $24→$5 | 重申 | →超重 |
| 2019年06月27日 | - | SVB Leerink | 评级下调 | 跑赢→市场表现 | |
| 2019年05月06日 | - | SVB Leerink | 开始承保 | →跑赢大盘 | |
| 2018年10月16日 | 147.63% | JMP证券 | $47→$34 | 维护 | 市场表现强于大盘 |
| 2018年3月28日 | 278.73% | 利林克·斯旺 | $54→$52 | 维护 | 跑赢大盘 |
| 2018年03月13日 | 293.3% | 利林克·斯旺 | $56→$54 | 维护 | 跑赢大盘 |
| 2018年02月09日 | 286.02% | 古根海姆 | →$53 | 开始承保 | →购买 |
What is the target price for Aclaris Therapeutics (ACRS)?
Aclaris Treeutics(ACRS)的目标价格是多少？
The latest price target for Aclaris Therapeutics (NASDAQ: ACRS) was reported by Cantor Fitzgerald on February 7, 2023. The analyst firm set a price target for $38.00 expecting ACRS to rise to within 12 months (a possible 176.77% upside). 4 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2023年2月7日报道了Aclaris治疗公司(纳斯达克：ACRS)的最新目标价。这家分析公司将目标价定为38美元，预计ACR将在12个月内上涨至(可能上涨176.77%)。去年有4家分析公司公布了评级。
What is the most recent analyst rating for Aclaris Therapeutics (ACRS)?
Aclaris治疗公司(ACRS)的最新分析师评级是多少？
The latest analyst rating for Aclaris Therapeutics (NASDAQ: ACRS) was provided by Cantor Fitzgerald, and Aclaris Therapeutics reiterated their overweight rating.
对Aclaris治疗公司(纳斯达克代码：ACRS)的最新分析师评级由坎托·菲茨杰拉德提供，Aclaris治疗公司重申其增持评级。
When is the next analyst rating going to be posted or updated for Aclaris Therapeutics (ACRS)?
Aclaris Treeutics(ACRS)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aclaris Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aclaris Therapeutics was filed on February 7, 2023 so you should expect the next rating to be made available sometime around February 7, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Aclaris治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Aclaris治疗公司的上一次评级是在2023年2月7日提交的，所以你应该预计下一次评级将在2024年2月7日左右的某个时候提供。
Is the Analyst Rating Aclaris Therapeutics (ACRS) correct?
分析师对Aclaris Treeutics(ACRS)的评级正确吗？
While ratings are subjective and will change, the latest Aclaris Therapeutics (ACRS) rating was a reiterated with a price target of $0.00 to $38.00. The current price Aclaris Therapeutics (ACRS) is trading at is $13.73, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Aclaris治疗(ACRS)评级被重申，目标价在0.00美元至38.00美元之间。Aclaris治疗公司(ACRS)目前的交易价格为13.73美元，在分析师的预测范围内。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧